What is MicroSure?
Founded in 2016 and headquartered in Eindhoven, Son, Netherlands, MicroSure is dedicated to enhancing patient outcomes through the development of advanced robotic systems for microsurgery. Its flagship product, MUSA, is recognized as the world's first surgical robot specifically engineered for open microsurgery. MUSA offers microsurgeons enhanced precision, enabling procedures previously unattainable by manual dexterity alone. The company's innovation stems from close collaboration between microsurgeons and engineers, ensuring its technology directly addresses critical needs in the field of microsurgery.
How much funding has MicroSure raised?
MicroSure has raised a total of $46.1M across 3 funding rounds:
Series A
$3M
Series B
$3.2M
Other Financing Round
$39.9M
Series A (2018): $3M with participation from Innovation industries
Series B (2021): $3.2M led by Invest-NL, Innovation Industries, Ten Cate Investeringsmaatschappij, and BOM Brabant Ventures
Other Financing Round (2023): $39.9M, investors not publicly disclosed
Key Investors in MicroSure
Invest-NL
Invest-NL is the national financing and development institution dedicated to fostering a sustainable and innovative Netherlands, accelerating and financing societal transitions in sectors such as Life Sciences & Health. They provide capital and expertise to invest in future solutions where the market hesitates.
Innovation Industries
Innovation Industries, Inc. designs and manufactures elevator fixtures and components, indicating a potential interest in advanced manufacturing and engineering solutions, which could extend to complex robotic systems.
Ten Cate Investeringsmaatschappij
Ten Cate Investeringsmaatschappij is a Dutch investment company, likely focused on supporting established and emerging Dutch enterprises across various sectors.
What's next for MicroSure?
With the recent major strategic investment and substantial overall financing, MicroSure is poised for significant growth and scaling. This capital is expected to fuel further research and development, potentially expanding the capabilities of the MUSA system or developing new robotic surgical solutions. The company's focus on a niche but critical area of medical technology, combined with strong investor backing, positions it for a prominent role in the future of surgical interventions. Future endeavors will likely involve broader market penetration, further clinical validation, and potentially strategic partnerships to accelerate adoption.
See full MicroSure company page
